Darren Tayama

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

Matthew D. Galsky, Jóse Ángel Arranz Arija, Aristotelis Bamias et al. · The Lancet · 2020 · 787 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

Robert J. Motzer, Romain Banchereau, Habib Hamidi et al. · Cancer Cell · 2020 · 561 citations · Full text

Medicine, Cancer Biology, Oncology +16

High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade

Kobe Yuen, Lifen Liu, Vinita Gupta et al. · Nature Medicine · 2020 · 439 citations · Full text

Life Sciences, Immunology, Oncology +16

Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study

Andrea Necchi, Richard W. Joseph, Yohann Loriot et al. · Annals of Oncology · 2017 · 322 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors

Guru Sonpavde, Juliane Manitz, Chen Gao et al. · The Journal of Urology · 2020 · 75 citations · Full text

Medicine, Oncology, Pharmacology +13